½ÃÀ庸°í¼­
»óǰÄÚµå
1385340

µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð : ¼Ö·ç¼Çº°, ¿ëµµº°, ÀûÀÀÁõº°, ºñÁî´Ï½º ¸ðµ¨º°, ¼¼°è ¿¹Ãø(-2032³â)

Digital Psychotherapeutics Market Size By Solution (Monotherapy, Combination), By Application (Prevention, Management, Treatment), By Indication (Phobias and Anxiety, Psychotic), By Business Model (Direct-to-patients, B2B) - Global Forecast to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 160 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð´Â Á¤½Å°Ç°­°ú À£ºù ÇÁ·Î±×·¥ÀÇ ½ÃÇà Áõ°¡¿¡ ÀÇÇØ 2023-2032³â 29.4%ÀÇ CAGRÀ» ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù.

Á÷¿ø Áö¿ø ÇÁ·Î±×·¥(EAP)°ú Á÷Àå³» À£´Ï½º ±¸»óÀÇ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ µðÁöÅÐ ½É¸®Ä¡·áÀÇ µµÀÔ·üÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÏ·Ê·Î Áö³­ 4¿ù, ij³ª´Ù ÃÖ°íÀÇ °¡»ó Ä¡·á ¹× À£´Ï½º ºê·£µåÀÎ ´ÙÀ̾ó·Î±×(Dialogue)´Â ÁøÈ­ÇÏ´Â Á¶Á÷³» Á¤½Å°Ç°­ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ »õ·Î¿î iCBT(ÀÎÅÍ³Ý ±â¹Ý ÀÎÁöÇൿġ·á) ÇÁ·Î±×·¥ÀÎ 'Á¤½Å°Ç°­(Mental Health)'À» ¹ßÇ¥Çß½À´Ï´Ù. ¹ßÇ¥Çß½À´Ï´Ù. º¸´Ù ¸Å·ÂÀûÀÌ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ µðÁöÅÐ ½É¸®Ä¡·á Ç÷§ÆûÀ» ±¸ÃàÇÏ¿© »ç¿ëÀÚÀÇ Âü¿©¿Í Ä¡·á ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇØ ±â¾÷ÀÌ »ç¿ëÀÚ °æÇè°ú µðÀÚÀÎÀ» Áß¿ä½ÃÇÏ°Ô µÇ¸é¼­ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» ½Ç¾îÁÙ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼Ö·ç¼Ç Ãø¸é¿¡¼­´Â Á¤½Å°Ç°­ »óŸ¦ Ä¡·áÇϱâ À§ÇÑ µ¶¸³Çü Ä¡·á·Î ¿©·¯ µðÁöÅÐ Åø ¹× °³ÀÔÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇϸ鼭 ´ÜÀÏ ¿ä¹ý ºÎ¹® ½ÃÀå ±Ô¸ð´Â 2023-2032³â 27.6%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ºÆ®·¹½º °¨¼Ò¿Í ºÒ¾È¿¡ ´ëÀÀÇϱâ À§ÇØ °¡ÀÌµå ¸í»ó ¼¼¼Ç, È£Èí¹ý, ¸¶À½Ã¬±è°ú ¸í»ó¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÌ¿Ï ±â¹ýÀ» Á¦°øÇÏ´Â ¾ÛÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áõ»óº°·Î´Â Á¤½ÅÀå¾Ö ºÐ¾ßÀÇ µðÁöÅÐ ½É¸®Ä¡·á ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö CAGR 30.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Á¤½Å ±³À°, ±¸»ó Àü·« ¹× Á¤½Åº´Àû Áõ»óÀ» °æÇèÇÏ´Â °³Àο¡°Ô Áö¿øÀ» Á¦°øÇÏ´Â µðÁöÅÐ Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ß»ýÇÕ´Ï´Ù. ȯÀڵ鿡°Ô Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ±âºÐ ÃßÀû ¹× Áõ»ó ¸ð´ÏÅ͸µ°ú ÇÔ²² µµÀԵǴ ¸ð¹ÙÀÏ ¿ëµµ ¹× ¿Â¶óÀÎ Ç÷§ÆûÀÇ °³¹ßÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áö¿ªº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µðÁöÅÐ ½É¸®Ä¡·á »ê¾÷ ±Ô¸ð´Â 2032³â±îÁö 31%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ Á¤½Å°Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á ¼¼¼Ç, ±âºÐ ÃßÀû, ¸í»ó ¿îµ¿ µîÀ» ÅëÇØ Á¤½Å°Ç°­ Áö¿øÀ» Á¦°øÇÏ´Â ¸ð¹ÙÀÏ ¿ëµµ°ú ¿Â¶óÀÎ Ç÷§ÆûÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ Áö¿øÀÇ ±ÞÁõ°ú ±â¾÷ÀÇ À£´Ï½º ÇÁ·Î±×·¥ Áõ°¡µµ ÀÌ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µðÁöÅÐ ½É¸®¿ä¹ý ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • Á¤½ÅÁúȯÀÇ À¯º´·ü »ó½Â
      • µðÁöÅÐ ½É¸®¿ä¹ý¿¡¼­ ±â¼ú Áøº¸ÀÇ Áõ°¡
      • Á¤½Å°Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ÀÓ»óÀû °ËÁõÀÇ °á¿©
      • ±â¼ú¿¡ ´ëÇÑ ¾×¼¼½º Á¦ÇÑ
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ±â¼úÀû ¹è°æ
  • °¸ ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¼Ö·ç¼Çº°

  • ÁÖ¿ä µ¿Çâ : ¼Ö·ç¼Çº°
  • ´Üµ¶¿ä¹ý
  • º´¿ë¿ä¹ý

Á¦6Àå µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • ¿¹¹æ
  • °ü¸®
  • Ä¡·á

Á¦7Àå µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÀûÀÀÁõº°

  • ÁÖ¿ä µ¿Çâ : ÀûÀÀÁõº°
  • °øÆ÷Áõ¡¤ºÒ¾ÈÀå¾Ö
  • Á¤½ÅÀå¾Ö
  • ±âŸ

Á¦8Àå µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ºñÁî´Ï½º ¸ðµ¨º°

  • ÁÖ¿ä µ¿Çâ : ºñÁî´Ï½º ¸ðµ¨º°
  • ȯÀÚ/¼ÒºñÀÚ¿¡ ´ëÇÑ Á÷Á¢ ÆÇ¸Å(D2P/C)
  • ±â¾÷ ´ë ±â¾÷(B2B)

Á¦9Àå µðÁöÅÐ ½É¸®¿ä¹ý ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Novartis AG
  • Pear Therapeutics
  • SilverCloud Health
  • Woebot Health
  • Starling Minds
  • SwissDT
  • AbleTo, Inc.
  • Spring Care, Inc
  • Meru
  • Ginger
KSA 23.12.05

Digital Psychotherapeutics Market size is poised to register 29.4% CAGR from 2023-2032, on account of the rising implementation of mental health and well-being programs. The growing importance of employee assistance programs (EAPs) and workplace wellness initiatives is witnessing the higher incorporation of digital psychotherapeutics. To illustrate, in April 2022, Canada's premier virtual care and wellness brand Dialogue introduced Mental Health+, its new iCBT (internet-based cognitive behavioural therapy) program for responding to the evolving mental health challenges in organizations. The greater emphasis laid by companies on user experience and designs for creating more engaging and user-friendly digital psychotherapeutic platforms to enhance user engagement and adherence to treatment will boost the market growth.

The overall digital psychotherapeutics industry is segmented based on solution, application, indication, business model, and region.

In terms of solution, the market size from the monotherapy segment may record 27.6% CAGR from 2023-2032 driven by the surging adoption of several digital tools and interventions as standalone treatments to treat mental health conditions. The increasing usage of apps providing guided meditation sessions, breathing exercises, and relaxation techniques focusing on mindfulness and meditation to cater to stress reduction and anxiety will also drive the market growth.

On the basis of indication, the digital psychotherapeutics market value from the psychotic disorders segment is expected to observe 30.8% CAGR through 2032. The growth can be attributed to the rising need for digital platforms to provide psychoeducation, coping strategies, and rendering support for individuals experiencing psychotic symptoms. The increasing developments in mobile applications and online platforms deployed with mood tracking and symptom monitoring to provide care to affected individuals will boost the segment expansion.

Regionally, Asia Pacific digital psychotherapeutics industry size is projected to record 31% CAGR through 2032. The growing awareness of mental health issues in the region is leading to the development of mobile applications and online platforms to render mental health support through therapy sessions, mood tracking, and meditation exercises. The surging government support and the rise in the number of corporate wellness programs will also add to the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & working
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact at global level
  • 1.6 Data validation
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Digital psychotherapeutics industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Solution trends
    • 2.1.4 Application trends
    • 2.1.5 Indication trends
    • 2.1.6 Business model trends

Chapter 3 Digital Psychotherapeutics Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of mental health disorders
      • 3.2.1.2 Increasing technological advancements in digital psychotherapeutics
      • 3.2.1.3 Growing awareness of mental health issues
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of clinical validation
      • 3.2.2.2 Limited access to technology
  • 3.3 Growth potential analysis
    • 3.3.1 By solution
    • 3.3.2 By application
    • 3.3.3 By indication
    • 3.3.4 By business model
  • 3.4 COVID- 19 impact analysis
  • 3.5 Regulatory scenario
  • 3.6 Technological landscape
  • 3.7 Gap analysis
  • 3.8 Future market trends
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategy dashboard, 2022

Chapter 5 Digital Psychotherapeutics Market Size and Forecast, By Solution (USD Million)

  • 5.1 Key trends, by solution
  • 5.2 Monotherapy
  • 5.3 Combination therapy

Chapter 6 Digital Psychotherapeutics Market Size and Forecast, By Application (USD Million)

  • 6.1 Key trends, by application
  • 6.2 Prevention
  • 6.3 Management
  • 6.4 Treatment

Chapter 7 Digital Psychotherapeutics Market Size and Forecast, By Indication (USD Million)

  • 7.1 Key trends, by indication
  • 7.2 Phobias and anxiety disorders
  • 7.3 Psychotic disorders
  • 7.4 Other indications

Chapter 8 Digital Psychotherapeutics Market Size and Forecast, By Business model (USD Million)

  • 8.1 Key trends, by business model
  • 8.2 Direct-to-patients/consumers
  • 8.3 Business-to-Business (B2B)

Chapter 9 Digital Psychotherapeutics Market Size and Forecast, By Region (USD Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East & Africa

Chapter 10 Company Profiles

  • 10.1 Novartis AG
  • 10.2 Pear Therapeutics
  • 10.3 SilverCloud Health
  • 10.4 Woebot Health
  • 10.5 Starling Minds
  • 10.6 SwissDT
  • 10.7 AbleTo, Inc.
  • 10.8 Spring Care, Inc
  • 10.9 Meru
  • 10.10 Ginger
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦